Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 2.14M | 3.28M | 2.89M | 3.65M | 1.53M |
Gross Profit | 2.06M | 3.21M | 2.62M | 3.19M | 1.09M |
EBITDA | -3.50M | -3.46M | -5.67M | -6.13M | -4.97M |
Net Income | -3.01M | -3.23M | -5.41M | -6.10M | -4.93M |
Balance Sheet | |||||
Total Assets | 6.95M | 6.35M | 9.22M | 14.72M | 18.97M |
Cash, Cash Equivalents and Short-Term Investments | 4.54M | 4.17M | 6.67M | 11.64M | 16.38M |
Total Debt | 542.23K | 239.37K | 332.26K | 357.96K | 476.31K |
Total Liabilities | 1.63M | 1.27M | 1.46M | 1.70M | 1.92M |
Stockholders Equity | 5.32M | 5.08M | 7.76M | 13.02M | 17.04M |
Cash Flow | |||||
Free Cash Flow | -2.35M | -2.91M | -4.97M | -4.93M | -4.33M |
Operating Cash Flow | -2.32M | -2.81M | -4.80M | -4.52M | -3.89M |
Investing Cash Flow | -132.93K | -35.20K | -118.20K | -408.02K | -441.45K |
Financing Cash Flow | 2.82M | 351.00K | -52.70K | 194.92K | 18.88M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
50 Neutral | AU$24.92M | ― | -93.06% | ― | 56.16% | -53.89% | |
46 Neutral | AU$6.96M | ― | -292.54% | ― | ― | 63.44% | |
44 Neutral | AU$1.47B | -5.90 | -41.17% | 4.21% | -3.35% | -41.14% | |
43 Neutral | AU$10.83M | ― | -16.63% | ― | -73.87% | -11.11% | |
40 Underperform | AU$10.10M | ― | -58.72% | ― | -26.94% | -4.08% | |
26 Underperform | AU$9.89M | ― | -146.25% | ― | ― | -68.70% |
Terragen Holdings Limited has made significant strides in expanding its product offerings and market reach. The company launched a new dry format probiotic product for ruminants, gaining traction in the livestock market, particularly in beef and lamb feedlots. Additionally, Terragen secured a US patent for its microbial feed supplement, enhancing its position in the global animal probiotics market. The company also reported promising results from its Great Land Plus® trials on maize crops, showcasing improved yield and cost efficiency. Furthermore, Terragen has initiated a Next Gen Nitrogen Project in collaboration with Queensland University of Technology to expand its plant product offerings.
Terragen Holdings Limited has been granted a US patent for its microbial feed supplement, Terragen Probiotic for Ruminants™ and MYLO®, by the United States Patent and Trademark Office. This patent, valid until 2041, provides intellectual property protection in the US, a key market for Terragen, and supports the company’s efforts to secure regulatory approvals for product launch. The patent strengthens Terragen’s position in the global animal probiotics market, highlighting the innovative outcomes of its research and development program.
Terragen Holdings Limited announced the resignation of its Chief Financial Officer and Company Secretary, Matthew Whyte, effective August 27, 2025, as he pursues other opportunities. The company is actively seeking his successor, and the transition is expected to impact its financial and administrative operations. The departure could influence Terragen’s strategic direction, given Whyte’s contributions to the company’s growth and development.